Korro Bio (KRRO) risk factors, FY2024 10-K

Risks Related to Our Business

1. 01We have incurred significant losses since inception. We expect to incur losses for the foreseeable future and may never achieve or maintain profitability
2. 02operate as a public company
3. 03We have never generated revenue from product sales and may never become profitable
4. 04attract top talent and retain qualified personnel
5. 05We will need substantial additional funding. If we are unable to raise capital when needed, we will be forced to delay, reduce, eliminate or prioritize among our research and development programs or future commercialization efforts
6. 06Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses. Many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their product candidates
7. 07changes in regulatory requirements and guidance that require amending or submitting new clinical protocols
8. 08experience damage to our reputation
9. 09If we experience delays or difficulties in the enrollment of patients in clinical trials, or other delays in our clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented

Risks Related to Discovery, Development and Commercialization

1. 10In addition, although we believe OPERA, our RNA editing platform, will position us to expand our portfolio of product candidates beyond the initial product candidates we may develop, we have not yet successfully developed any product candidate and our ability to expand our portfolio may never materialize
2. 11authorities in other countries or jurisdictions. Approval processes vary among countries and can involve additional product candidate testing and validation and additional administrative review periods
3. 12RNA editing is a novel technology with limited clinical validation for human therapeutic use. The approaches we take to discover and develop novel therapeutics are unproven and may never lead to marketable products
4. 13We are very early in our development efforts, and our preclinical studies and clinical trials may not be successful. If we are unable to commercialize our product candidates or experiences significant delays in doing so, our business will be materially harmed
5. 14European Union, or EU, and Australia, where we recently dosed the first participants in our Phase 1/2a REWRITE clinical trial of KRRO-110 for AATD
6. 15establishment and maintenance of healthcare coverage and adequate reimbursement by payors
7. 16Any product candidates we develop may fail in preclinical or clinical development or be delayed to a point where they do not become commercially viable
8. 17varying interpretations of data by the FDA and similar foreign regulatory agencies
9. 18We may not be able to conduct clinical trials successfully due to various process-related factors that could negatively impact our business plans
10. 19If we cannot successfully manufacture our product candidates for our research and development and preclinical activities, or manufacture sufficient amounts of our product candidates to meet our clinical requirements and timelines, our business may be materially harmed
11. 20The process of manufacturing oligonucleotides is complex and we may encounter difficulties in production, particularly with respect to process development or scaling-up of our manufacturing capabilities
12. 21We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success
13. 22Our product candidates may cause undesirable and unforeseen side effects or be perceived by the public as unsafe, which could delay or prevent their advancement into clinical trials or regulatory approval, limit the commercial potential or result in significant negative consequences
14. 23If we are unable to successfully identify patients who are likely to benefit from therapy with any product candidates we develop, or experience significant delays in doing so, we may not realize the full commercial potential of any products we may develop
15. 24we may not realize the full commercial potential of any product candidates we develop that receive marketing approval if, among other reasons, we are unable to appropriately select patients who are likely to benefit from therapy with our products
16. 25If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to market and sell any product candidates, we may be unable to generate any revenues
17. 26Even if we receive regulatory approval to market our product candidates, the market may not be receptive to our product candidates upon their commercial introduction, which will prevent us from becoming profitable
18. 27The pharmaceutical industry is intensely competitive. If we are unable to compete effectively with existing drugs, new treatment methods and new technologies, we may be unable to commercialize successfully any drugs that we develop
19. 28collaborative arrangements in our target markets with leading companies and research institutions
20. 29The pricing, insurance coverage and reimbursement status of newly approved products is uncertain. Failure to obtain or maintain adequate coverage and reimbursement for our product candidates, if approved, could limit our ability to market those products and decrease our ability to generate product revenue
21. 30If the market opportunities for any product candidates we may develop are smaller than we believe they are, our potential revenues may be adversely affected, and our business may suffer

Risks Related to Regulatory, Legal, and Clinical Trials

1. 31Because we are developing oligonucleotides, which are considered a relatively new class of drugs, there is increased risk that the outcome of our clinical trials will not be sufficient to obtain regulatory approval
2. 32Enacted and future legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates and may affect the prices we may set
3. 33Even if we complete the necessary preclinical studies and clinical trials, we cannot predict when, or if, we will obtain regulatory approval to commercialize a product candidate and the approval may be for a narrower indication than we seek
4. 34the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval
5. 35We may be unable to obtain regulatory approval in the United States or foreign jurisdictions and, as a result, be unable to commercialize our product candidates and our ability to generate revenue will be materially impaired
6. 36certain safe-use criteria, and requiring treated patients to enroll in a registry, among other requirements. These limitations and restrictions may limit the size of the market for the product and affect reimbursement by third-party payors
7. 37injunctions or the imposition of civil or criminal penalties
8. 38Any drugs we develop may become subject to unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives, thereby harming our business
9. 39We may not be able to obtain orphan drug exclusivity for one or more of our product candidates, and even if we do, that exclusivity may not prevent the FDA or the EMA from approving other competing products
10. 40exclusivity period in the European Union can be reduced to six years if a product no longer meets the criteria for orphan designation, in particular if the product is sufficiently profitable so that market exclusivity is no longer justified
11. 41If we do not comply with laws regulating the protection of the environment and health and human safety, our business could be adversely affected
12. 42If we or our collaborators, manufacturers, service providers or other third parties fail to comply with applicable healthcare laws and regulations, we could be subject to enforcement actions, which could affect our ability to develop, market and sell our products and may harm our reputation
13. 43civil and criminal penalties, up to and including criminal prosecution resulting in fines, exclusion from healthcare reimbursement programs and imprisonment
14. 44Our employees, consultants and collaborators may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements
15. 45Product liability lawsuits against us could cause us to incur substantial liabilities and could limit commercialization of any medicines that we may develop
16. 46the inability to commercialize any medicines that we may develop
17. 47Our internal computer and information systems, or those used by our CROs, CMOs or other contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of our development programs
18. 48We may be unable to adequately protect our information systems from cybersecurity incidents, which could result in the disclosure of confidential information, damage our reputation, and subject us to significant financial and legal exposure
19. 49Our failure to obtain regulatory approval in international jurisdictions would prevent us from marketing our product candidates outside the United States
20. 50We, our collaborators and our service providers may be subject to a variety of privacy and data security laws, regulations and contractual obligations, and our failure to comply with them could harm our business

Risks Related to Our Third Party Relationships

1. 51We expect to rely on third parties to conduct our clinical trials and some aspects of our research, as well as some aspects of our delivery methods, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials, research or testing
2. 52We may not be successful in finding strategic collaborators for continuing development of certain of our product candidates or successfully commercializing or competing in the market for certain indications; and we may not see any benefit from our collaboration agreement with Novo Nordisk
3. 53Future acquisitions or strategic alliances could disrupt our business and harm our financial condition and results of operations
4. 54litigation or other claims in connection with the acquired company, including claims from terminated employees, customers, former stockholders or other third parties
5. 55We rely, and anticipate that we will rely, on third parties to design, conduct, supervise and monitor our preclinical studies and clinical trials, and if those third parties perform in an unsatisfactory manner, it may harm our business
6. 56We rely on third parties in the supply and manufacture of our product candidates for our research, preclinical and clinical activities, and may do the same for commercial supplies of our product candidates
7. 57Some state laws also require pharmaceutical companies to comply with specific compliance standards, restrict financial interactions between pharmaceutical companies and healthcare providers or require pharmaceutical companies to report information related to payments to health care providers or marketing expenditures

Risks Related to Our Personnel, Operations and Growth

1. 58If we are unable to attract and retain qualified key management and scientists, staff, consultants and advisors, our ability to implement our business plan may be adversely affected
2. 59We expect to expand our research, development, delivery, manufacturing, commercialization, regulatory and future sales and marketing capabilities over time, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations

Risks Related to Intellectual Property

1. 60If we are not able to obtain or protect intellectual property rights related to any of our product candidates, development and commercialization of our product candidates may be adversely affected
2. 61Our pending patent applications may not issue as patents, and even issued patents may not provide sufficient protection of our RNA editing platform OPERA and our product candidates
3. 62We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might adversely affect our ability to develop and market our product candidates
4. 63We may be involved in lawsuits to protect or enforce our patents, which could be expensive, time consuming and unsuccessful
5. 64Our commercial success depends in part on our ability to develop, manufacture, market and sell our product candidates and use our proprietary technologies without infringing, misappropriating or otherwise violating the intellectual property or proprietary rights of third parties
6. 65there could be public announcements of the results of hearings, motions, or other interim proceedings or developments, and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock
7. 66We may not be successful in acquiring or in-licensing necessary rights to key technologies or any product candidates we may develop
8. 67We may become subject to claims challenging the inventorship or ownership of our patents and other intellectual property
9. 68Third parties may assert that our employees, consultants, or advisors have wrongfully used or disclosed confidential information or misappropriated trade secrets
10. 69Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements
11. 70We have limited foreign intellectual property rights and may not be able to protect our intellectual property and proprietary rights throughout the world
12. 71Changes in patent law in the United States and in non-U.S. jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our RNA editing platform technology and product candidates
13. 72If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed
14. 73confidential or proprietary information, such as our trade secrets, were to be disclosed or misappropriated, or if any of that information was independently developed by a competitor, our competitive position could be harmed
15. 74Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time
16. 75If we do not obtain PTE and data exclusivity for any product candidates we may develop, our business may be materially harmed
17. 76Intellectual property rights do not necessarily address all potential threats
18. 77Our use of open source software could impose limitations on our ability to commercialize our product candidates
19. 78If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected
20. 79Our business could be materially and adversely affected in the future by the effects of disease outbreaks, epidemics and pandemics
21. 80Our operations are vulnerable to interruption by disasters, terrorist activity, pandemics and other events beyond our control, which could harm our business
22. 81Litigation costs and the outcome of litigation could have a material adverse effect on our business
23. 82The price of our common stock is volatile and fluctuates substantially, which could result in substantial losses for our stockholders
24. 83period-to-period fluctuations in our financial results
25. 84We are incurring and expect to continue to incur additional costs and increased demands upon management as a result of complying with the laws and regulations affecting public companies
26. 85Once we are no longer a smaller reporting company or otherwise no longer qualify for applicable exemptions, we will be subject to additional laws and regulations affecting public companies that will increase our costs and the demands on management and could harm our operating results and cash flows
27. 86If we fail to maintain proper and effective internal controls, our ability to produce accurate financial statements on a timely basis could be impaired
28. 87Our certificate of incorporation and bylaws and provisions under Delaware law could make an acquisition of us more difficult and may prevent attempts by our stockholders to replace or remove our management
29. 88require the approval of the holders of at least 66.67% of the votes that all our stockholders would be entitled to cast to amend or repeal certain provisions of our charter or bylaws
30. 89We do not anticipate that we will pay any cash dividends in the foreseeable future
31. 90An active trading market for our common stock may not continue to develop or be sustained and our stockholders may not be able to resell their shares of common stock for a profit, if at all
32. 91Future sales of shares by existing stockholders could cause our stock price to decline
33. 92Our executive officers, directors and principal stockholders have the ability to control or significantly influence all matters submitted to our stockholders for approval
34. 93If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about us, our business or our market, our stock price and trading volume could decline
35. 94We will have broad discretion in the use of our cash and cash equivalents and may invest or spend our cash in ways with which you do not agree and in ways that may not increase the value of your investment
36. 95Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates we may develop
37. 96Changes in tax laws or in their implementation or interpretation may adversely affect our business and financial condition
38. 97Our ability to utilize our net operating loss, or NOL, carryforwards and certain other tax attributes may be limited
39. 98Unfavorable global economic conditions could adversely affect our business, financial condition, results of operations or cash flows
40. 99Our business may be impacted by macroeconomic conditions, including fears concerning the financial services industry, inflation, rising interest rates and volatile market conditions, and other uncertainties beyond our control